All In Biotech

Drug Trial Radar · NCT07570316

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

230

Planned (sponsor's estimate)

Start

Jun 10, 2026

Primary completion

Jun 2028

Study completion May 2030

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
May 6, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it. The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment. The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment. More information can be found here: https://clinicaltrials.argenx.com/vitalithy

Conditions

  • Graves' Disease
  • Graves Disease

Interventions

  • Efgartigimod PH20 SCBiological

    Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)

  • Placebo PH20 SCOther

    Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part ATime frame: Up to 24 weeks (part A)

Locations

35 sites in 3 countries. Site status is shown where the registry gives one.

  • Profound Research LLC at Tri-City Primary Care

    Carlsbad, California · Recruiting

  • Diabetes Associates Medical Group

    Orange, California · Recruiting

  • Pasadena Clinical Trials

    Pasadena, California · Recruiting

  • Havana Research Institute LLC.

    Pasadena, California · Recruiting

  • San Jose Clinical Trials

    San Jose, California · Recruiting

  • Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park Location

    Fleming Island, Florida · Recruiting

  • The Center for Diabetes and Endocrine Care

    Fort Lauderdale, Florida · Recruiting

  • University of Florida Jacksonville College of Medicine

    Jacksonville, Florida · Recruiting

  • Ilumina Medical Research LLC

    Kissimmee, Florida · Recruiting

  • Oceane 7 Medical & Research Center, Inc

    Miami, Florida · Recruiting

  • Johnson County Clin-Trials, Inc.

    Lenexa, Kansas · Recruiting

  • Alliance for Multispecialty Research, LLC

    Wichita, Kansas · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Metro Detroit Endocrinology Center

    Dearborn, Michigan · Recruiting

  • Profound Research

    Farmington Hills, Michigan · Recruiting

  • Truman Medical Center

    Kansas City, Missouri · Recruiting

  • Albany Medical College Community Endocrinology

    Albany, New York · Recruiting

  • Endocrine Associates of West Village PC

    New York, New York · Recruiting

  • Asheville Clinical Research

    Asheville, North Carolina · Recruiting

  • Wake Internal Medicine Consultants

    Raleigh, North Carolina · Recruiting

  • Research Institute of Dallas

    Dallas, Texas · Recruiting

  • Frontier Medical Center - Academy of Diabetes Thyroid and Endocrine

    El Paso, Texas · Recruiting

  • Juno Research

    Houston, Texas · Recruiting

  • Clinic of Endocrinology

    Houston, Texas · Recruiting

  • Tekton Research Irving

    Irving, Texas · Recruiting

  • Biopharma Informatic, LLC

    McAllen, Texas · Recruiting

  • Tekton Research - McKinney

    McKinney, Texas · Recruiting

  • Southern Endocrinology Associates PA

    Mesquite, Texas · Recruiting

  • Consano Clinical Research

    Shavano Park, Texas · Recruiting

  • LLC American Hospital Network

    Tbilisi, Georgia · Recruiting

  • LTD Israeli-Georgian Medical Research Clinic Healthycore

    Tbilisi, Georgia · Recruiting

  • New Hospitals

    Tbilisi, Georgia · Recruiting

  • LLC Todua Clinic

    Tbilisi, Georgia · Recruiting

  • In Vitro Fertilization Center LLC

    Tbilisi, Georgia · Recruiting

  • Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust)

    Gateshead, Tyne and Wear, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.